Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
CFZ533 - Blocking, non-depleting, Fc-silent, anti-CD40
monoclonal antibody
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03663335 CIRRUS I (CCFZ533A2201)
Kidney transplantation
Phase 2
325
Proportion of patients with composite event (BPAR, Graft Loss or Death) at M12
Two cohorts: de novo TX and maintenance
Test Arms: CFZ533 + MMF + corticosteroids
Standard of Care: TAC + MMF + corticosteroids
Kidney transplant recipients
NCT03905525 TWINSS (CCFZ533B2201)
Sjögren's syndrome
Phase 2
260
Change in EULAR Sjögren's syndrome Disease Activity Index (ESSDAI) score and
EULAR Sjögren's syndrome Patient Reported Index (ESSPRI) score
Three dose arms of CFZ533
Placebo
Target Patients
Read-out Milesstone(s)
2022
Publication
2022
72 Investor Relations | Q2 2021 Results
Patients with Sjögren's syndrome
2022
2022
NOVARTIS | Reimagining MedicineView entire presentation